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Abstract
Background: Currently, the most promising therapies for Duchenne muscular dystrophy (DMD) are exon skipping
and stop codon read-through, two strategies aimed at restoring the expression of dystrophin. A phase 3 clinical trial
with drisapersen, a drug designed to induce exon 51-skipping, has failed to show significant improvement of the
primary outcome measure, the six-minute walk test.
Discussion: Here, we review some key points that should be considered when designing clinical trials for these new
therapies. First, younger patients have more functional abilities and more muscle fibers to preserve than older patients
and therefore are better subjects for trials designed to demonstrate the success of new treatments. Second, the inclusion
of patients on corticosteroids both in the treatment and placebo groups is of concern because the positive effect of
corticosteroids might mask the effect of the treatment being tested. Additionally, the reasonable expectation from these
therapies is the slowing of disease progression rather than improvement. Therefore, the appropriate clinical endpoints are
the prolongation of the ability to stand from the floor, climb stairs, and walk, not an increase in muscle strength or
function. Hence, the time frames for the detection of new dystrophin, which occurs within months, and the ability to
demonstrate a slowing of disease progression, which requires years, are strikingly different. Finally, placebo-controlled
trials are difficult to manage if years of blindness are required to demonstrate a slowing of disease progression. Thus,
accelerated/conditional approval for new therapies should be based on surrogate biochemical outcomes: the
demonstration of de novo dystrophin production and of its beneficial effect on the functional recovery of muscle fiber.
Summary: These data suggest that clinical trials for DMD patients must be adapted to the particular characteristics of the
disease in order to demonstrate the expected positive effect of new treatments.
Keywords: Duchenne muscular dystrophy, Dystrophin evaluation, Clinical trial, Corticosteroid treatment, Exon skipping,
Splice modulation
Background
Currently, the most promising therapies for Duchenne
muscular dystrophy (DMD) include two small-molecule
approaches, exon skipping and stop codon read-through,
both of which aim to restore the expression of dys-
trophin from the mutant endogenous gene. With respect
to exon skipping, the preclinical studies in mdx mouse
models of DMD have demonstrated very impressive
dose-dependent production of dystrophin and a thera-
peutic effect on dystrophic muscles [1]. In DMD pa-
tients, two chemistries targeting dystrophin exon 51,
drisapersen, a 2’-O-methyl-phosphorothioate (2OMePS),
and eteplirsen, based on phosphoramidate morpholino
(PMO), both elicited the expected exon 51 skipping and
local dystrophin restoration following intramuscular in-
jection [2, 3]. However, the 186-patient phase 3 clinical
trial with drisapersen (NCT01254019) failed to show a
significant improvement of the primary outcome measure,
the six-minute walk test (6MWT) [1]. In a subsequent
phase 2 study, the boys in the continuous drisapersen
group demonstrated transient improvements in 6MWT
compared with those receiving the placebo but not in
the other clinical outcome measures, including the time
to stand, time to run 10 m, and time to climb stairs [4].
As in previous studies [5], there was very limited
evidence of drug-induced dystrophin production in
patient’s muscles [6].
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Eteplirsen has been associated with more evident de
novo dystrophin production than drisapersen in two
studies [6–8]. In the open-label extension study, there
was also stabilization of the clinical outcome in a subset
of patients [7]. However, it remains to be seen whether
eteplirsen can maintain a significant long-term clinical
benefit [1]. In the second study [8], two patients treated
with eteplirsen lost ambulation despite a consistent
increase in dystrophin-positive fibers.
In a phase 2b trial that included 174 patients, ataluren,
designed to permit stop codon read-through, was associ-
ated with a marginally significant improvement in the
6MWT compared with the placebo [9]. However, this
drug has shown no clear evidence of facilitating dys-
trophin restoration [10], and the scoring method used in
the trial was considered very subjective [11–14].
The failure of the only phase 3 study of antisense oli-
gonucleotides (drisapersen) performed so far has raised
considerable discussion about the validity of dystrophin
as a biomarker and the 6MWT as an outcome measure
[1, 6, 11, 12, 15]. However, other critical points have not
been considered. In this article, we review some of the
characteristics of DMD that should influence the trial
design for DMD treatments. We first review recent lit-
erature documenting the possibility of earlier clinical
diagnosis of DMD and the indications that the disease
has already a progressive course during infancy. Next we
document the beneficial effects of corticosteroid treat-
ment to highlight the fact that the inclusion of patients
on corticosteroids in both the treatment and control
groups may be problematic. We then focus on the im-
portance of choosing clinical outcome measures that
match the type of improvement expected from treat-
ment. The clinical endpoints that are appropriate if the
effect of treatment is amelioration are not appropriate if
the expected impact is slowing disease progression.
Finally, we propose a way to comply with the require-
ment that a correlation be shown between dystrophin
expression and clinical outcomes, realizing that the pro-
duction of dystrophin can take months but slowing of
disease progression requires years to demonstrate.
Discussion
DMD: early onset and progressive course
The X-linked, progressive, muscle-wasting disease DMD
is caused by mutations in the gene encoding dystrophin.
DMD is a fatal neuromuscular disease, affecting 1 in
3500–6000 live male births [16, 17]. In affected boys, a
diagnosis can be suspected at birth on the basis of mark-
edly elevated levels of serum creatine kinase (CK), and
eventually confirmed with genetic or dystrophin analysis.
In the past, most patients were diagnosed around the
age of 5 and observed to subsequently show some im-
provement in motor skills, albeit at a slower rate than
normal boys (the “honeymoon” period in DMD) [18].
Recently, the clinical course of the disease has been bet-
ter defined using assessment scales validated in infants
from birth. Significant deficits in gross and fine motor
function are already present in infants and young boys
[19]. Motor function further declines within the first
3 years of life compared with age-matched peers [20].
Boys with DMD have a progressive muscle weakness,
with a 50-60 % drop in strength by age 5 [20]. The loss
of clinical milestones occurs in a predictable descending
order: loss of standing from the floor, loss of stairs
climbing, and loss of ability to walk independently [21].
Respiratory, orthopedic, and cardiac complications emerge
in wheelchair-bound DMD patients [22]. Progressive
scoliosis develops in over 90 % of patients as a com-
bined result of wheel-chair dependence, paralysis of the
extensor muscles [23], contractures, and growth spurts.
Lung function increases up to the age of 10–12, plateaus,
and then decreases, with an estimated loss of 10 % per
year of forced vital capacity (FVC) [24]. Without treat-
ment, death occurs in the early- to mid-teens due to
cardiorespiratory compromise [17]. The provision of
non-invasive mechanical ventilation, assisted coughing,
and cardio-protective medication allows survival into
the late twenties and thirties [25].
The early onset and progressive clinical course of the
disease is matched by the laboratory findings. The CK
level, a biochemical marker of muscle necrosis, is 50- to
100-fold above normal in affected fetuses, at birth, and
during the first year, decreases around the time when
affected boys become wheel chair-bound (age 8–10), and
only approaches normal values in the very late stages of
the disease [26, 27]. Abnormal findings on muscle biopsy
have been detected from DMD fetuses as early as the
second trimester of pregnancy [26] and in DMD infants
at 40 days [28] and 4 months of age [29].
Clinical trials: starting time
The design of clinical trials in DMD should take in
consideration that the disease has an early onset and a
progressive, predictable course [21]. The diagnosis of
DMD is now feasible much earlier than in the past. The
marked elevation of CK is already present at birth. A
florid dystrophic process is evident in the muscle biopsy
of affected newborns. Within their first 3 years of life,
DMD infants and young boys show measurable deficits
in gross and fine motor function. In addition, their
motor function declines within the first 3 years of life
compared with age-matched peers. Having recognized
that the dystrophic process is biologically and clinically
present and measurable at an early age, there is no rea-
son to delay treatment until the age of 7, when muscle
weakness and myofiber loss are already advanced. Older
boys with DMD have less muscle to rescue by exon
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skipping or any other approach and more fibrous and
fatty connective tissue between myofibers, reducing con-
traction efficiency and possibly impairing regeneration [1].
Beneficial effect of corticosteroids
The first scientific evidence of the beneficial effect of
corticosteroids in DMD was documented over 40 years
ago by Drachman [30]. Since then, several other studies
have demonstrated the efficacy of corticosteroid therapy
in delaying the loss of independence and autonomous
ambulation and in maintaining adequate pulmonary
function [31]. Currently, corticosteroids are the gold
standard treatment for muscle weakness in ambulant
children with DMD [31]. The most common daily dos-
age regimes are 0.75 mg/kg/day prednisone/prednisol-
one and 0.9 mg/kg/day deflazacort [31]. Other studies
using corticosteroids with various combinations of daily,
alternate-day, or cyclical prednisone treatment [32–35]
have also demonstrated benefit in functional parameters.
Corticosteroids are now routinely prescribed in most
countries for DMD patients; however, there is no con-
sensus on the optimal age to initiate treatment and the
optimal dose and dosage schedule [31, 36].
Despite the fact that most of the different dosage
schedules claim to be effective in improving muscle
strength and function, none has been shown to maintain
this result with time [31, 33, 37–43]. All long-term studies,
independent of dose and dosage schedule, have shown
that after a variable period of “improvement,” patients
invariably lose muscle strength and function, although at a
slower rate than patients not treated with corticosteroids.
In summary it is now widely recognized that long-
term corticosteroid therapy (1) prolongs ambulation, (2)
reduces the need for spinal surgery, (3) reduces cardio-
pulmonary dysfunction, (4) delays the need for mech-
anical ventilation, and (5) increases survival and quality
of life of DMD patients [20, 31, 35, 41, 42, 44]. Recent
findings also indicate that early use of corticosteroids is
associated with significant advantages over delaying its
use [20, 28, 35].
The inclusion of patients on corticosteroids both in
the treatment and placebo groups is of concern because
the positive effect of corticosteroids may mask the effect
of the treatment being tested. On the other side, cur-
rently, corticosteroid therapy is the only recognized ef-
fective treatment for DMD patients; thus, avoiding its
use may be difficult or possibly ethically unacceptable.
However, it seems that parents of DMD patients are
willing to accept more uncertainty and take greater risk
early on due to the predictable outcome of the disease
[45]. In addition, according to a WMA press release in
2001 [46], a placebo-controlled trial may be ethically
acceptable even if proven therapy is available if there are
compelling and scientifically sound methodological reasons
justifying the need for such a study to determine the effi-
cacy of a therapeutic method. The clinical trials of the new
emerging therapies have followed two different and ques-
tionable approaches regarding the inclusion of patients on
corticosteroids. In the exon-skipping trials, the patients
were randomized to receive the test agent or placebo in
addition to their current corticosteroid therapy [4, 8]. In
this add-on trial design, efficacy is established only for the
combination treatment rather than the added new drug as
monotherapy. In an add-on trial, it is desirable to recruit
patients on the same maintenance therapy or at least to
stratify based on the different treatments. In one study [8],
12 patients were receiving 2 different corticosteroids at 4
different doses and dosage regimens. In the ataluren trial,
70 % of patients in the two arms of the study were re-
ceiving corticosteroids [8] with very different doses and
regimens, thereby raising questions as to the validity of
the interpretation of clinical outcomes.
Clinical trials: treatment expectations
A clinical trial design should reflect the type of clinical
benefit that is expected from treatment and the time
required to demonstrate benefit. The positive effects of
intervention on the course of a chronic progressive dis-
ease like DMD may involve 1) arresting the course of
disease with or without restoration of the lost function
or 2) slowing the progression of the disease (Fig. 1).
The choice of clinical trial endpoints should take into
consideration these two different expectations. If the ex-
pectation of the intervention is arresting the course of
the disease, that is, stopping the loss of muscle fibers,
then an increase or conservation of muscle strength or
muscle function are suitable endpoints to evaluate effi-
cacy. However, these endpoints are not appropriate for
an intervention that is only expected to slow disease
progression. In this case, muscle strength (maximal iso-
metric muscle force, FVC) or muscle function (6MWT)
may show a transient improvement at some point in
time; however, they are expected to deteriorate with
time, although at a slower rate compared with no treat-
ment. Some endpoints appropriate for demonstrating a
slowed disease progression are 1) survival to death, 2)
survival to death or any respiratory intervention or 3)
prolongation of independent walking. It is evident that
all of these endpoints require a long period of treat-
ment/observation, particularly if treatment is started
early during the course of the disease. This point was
well demonstrated by a prospective, long-term, open-
label study of treatment with alternate-day corticoste-
roids in five 2- to 4-year-old DMD patients. This study
had prolongation of the ability to walk as primary out-
come measure [28, 35, 47]. At the last follow-up, four of
these five patients, aged 16 to 18, were fully ambulant,
and three of them could still climb stairs. Muscle
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strength, measured with a myometer, increased slightly
from age 5 to 8 and then declined steadily. This progres-
sive decline was particularly evident and dramatic for
the knee extensors, with an average of 122 N at age 8,
80 N at age 12, 55 N at age 16, and 44 N at age 18 [35].
This study suggests that long-term corticosteroid treat-
ment is effective in prolonging function but not in re-
covering muscle strength and lost function and its early
use seems appropriate. In summary, at best, the effect
of corticosteroid treatment is to slow the progressive
course of the disease [33, 35, 48, 49]. A reasonable and
primary expectation for trials of new DMD therapies is
the preservation of independent ambulation beyond the
age of 12 [50]. During the typical time frame of a clinical
trial, one year, increasing the distance walked during a
6MWT by 30 or more meters or reducing the time
required for a 10-m walk by a few seconds does not
guarantee that patients will be able to walk longer, the
definition of treatment success. The easiest way to
evaluate the preservation of ambulation is to use the
timed 10-m test to determine the velocity expressed in m/s.
In this way, all the patients can be scored, including those
who are no longer able to walk.
The next question is “What type of clinical result is
foreseeable for any treatment aimed at de novo production
of dystrophin in DMD patients?” A complete, long-lasting
restoration of dystrophin around all of the residual myofi-
bers in DMD patients is too optimistic. Becker muscular
dystrophy (BMD) patients with in-frame deletions includ-
ing exon 51 typically have a milder phenotype and longer
life span than DMD patients [51, 52]; however, in these
patients, the shortened dystrophin is present from birth. A
treatment begun in a DMD boy after age 7 will at best re-
sult in a phenotype somewhere between that of a moder-
ately severe BMD patient and a less progressive DMD
patient. BMD is clinically defined as a patient remaining
ambulant at least age 16 or later [17]. Hence, any DMD
treatment should be considered effective if it is able to
prolong ambulation at least beyond the age of 16, a result
that has already been achieved in some DMD patients
with early or long-term corticosteroid therapy [35, 38, 43].
Dystrophin evaluation
Currently, the quantification of newly produced dys-
trophin is the earliest endpoint to evaluate and to deter-
mine the efficacy of antisense oligonucleotides or stop
codon read-through treatments [6]. Promising tools such
as melanocytes, spectroscopy, and other miRNAs have
yet to be validated [1, 15, 53, 54]. The methods that are
presently used to evaluate the presence of dystrophin,
western blot (WB) and immunofluorescence (IF), are
actually semi-quantitative methods that determine the
signal of dystrophin normalized to an internal marker
and expressed relative to control. This implies that only
the samples examined in the same experiment can be
compared (same session IF or loaded together in the
same gels used for a WB) and that it is incorrect to com-
pare results obtained with samples tested at different
times or in different laboratories.
There is no doubt that standard operating procedures
for the detection of dystrophin [1, 55–57] are needed;
however, two considerations are relevant on this regard.
Fig. 1 DMD course and treatment outcomes. A DMD boy beginning treatment at age 5 (arrow) when he has already lost some motor function/muscle
strength (line A) compared with normal peers (line N). Without treatment, he will continue to deteriorate, finally loosing ambulation between 7–12 years
of age (black triangle – B). The red area (C) represents the outcome of a treatment able to arrest (base of the red trapezoid) or partially or completely to
restore (leg of the trapezoid) lost function. The green area (D) represents the outcome of a treatment able to slow the progression of the disease with
loss of autonomous ambulation after the age of 14 years
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First, the procedures used to date are all acceptable as
semi-quantitative methods, and yet, all of the methods
are questionable as quantitative methods. Second, if we
grant that the fragment of muscle analyzed reflects the
situation in the whole muscle, still it remains to be
established the relationship between the amount of newly
synthesized dystrophin and the functionality of the cell.
Dystrophin expression and clinical outcome
The approval of exon skipping and splice modulation
treatments as therapies for DMD requires that a correl-
ation be shown between dystrophin expression and clin-
ical outcomes. Although dystrophin can be produced
within months, prolongation of walking, the desired clinical
outcome, can take years to be demonstrated, especially if
treatment is started early. Because of this challenge, accel-
erated approval should be based on a surrogate biochem-
ical outcome (e.g., demonstration of de novo dystrophin
production in muscle). Most important, if we grant that
the fragment of muscle analyzed reflects the situation in
the whole muscle, once it has been shown that newly pro-
duced dystrophin is detectable in response to a treatment
designed to restore dystrophin, its effect on the functional
recovery of muscle fiber should be demonstrated. A second
biological end point is thus needed. For example, in a base-
line muscle biopsy, a lack of dystrophin and a cell dysfunc-
tion (e.g., secondary deficiency of the dystrophin-associated
glycoprotein complex, mitochondrial dysfunction, defective
autophagy, etc.) are shown. In the post-treatment muscle
biopsy, a significant increase of dystrophin [6] and cor-
rection of the cell dysfunction should be demonstrated.
If a treatment satisfies both the biological endpoints,
application for accelerated approval could be made.
Placebo-controlled trials are also not an option if a decade
or more of blindness is needed to show a slowing of
disease progression in the treated group compared with
the placebo group.
Summary
We suggest ways to overcome the problems associated
with the previous and on-going DMD clinical trial de-
signs. First, younger patients have more muscle fibers to
rescue and functional abilities to preserve and are thus
more suitable patients in which to demonstrate long-
lasting success of the new treatments. Second, the inclu-
sion of patients on corticosteroids in both the treatment
and placebo groups should be avoided because the posi-
tive effect of corticosteroids might mask the effect of the
treatment being tested. Third, the reasonable expect-
ation from these therapies is the slowing of disease pro-
gression, not long-lasting improvement. Therefore, the
appropriate clinical endpoints are prolongation of the
ability to stand from the floor, climb stairs, and walk ra-
ther than an increase of muscle strength or function.
Fourth, the production of dystrophin can occur within
months, but the slowing of disease progression requires
years to demonstrate. Because of this gap in time, the
accelerated/conditional approval of new DMD therapies
should be based on surrogate biochemical outcomes:
demonstration of de novo dystrophin production and
its beneficial effect on the functional recovery of
muscle fiber.
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